Chong‐Rui Xu
0000-0002-3474-2809
Publication & Citation Trends
Publications
0 total
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
Cited by 1
Semantic Scholar
Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?—A Case Report
Cited by 0
Semantic Scholar
PP01.42: Efficacy and Multi-omics Insights of Immune Checkpoint Inhibitors in NSCLC with Leptomeningeal Metastasis
Cited by 0
Semantic Scholar
PP01.54: The Outcome of Pemigatinib in Advanced NSCLC With A Novel FGFR Fusion: Case Report
Cited by 0
Semantic Scholar
PP01.01: Association and Prognosis of Non-Cancerous Respiratory Diseases to Lung Cancer and Pan-Cancer: Observational and Mendelian Randomization Analysis
Cited by 0
Semantic Scholar
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Cited by 18
Semantic Scholar
Causal relationship between oral/gut microbiota and lung cancer: a two-sample Mendelian randomization study
Cited by 1
Semantic Scholar
Letter Regarding "Revolutionizing NSCLC Treatment: Unleashing the Potential of IBI351 and Its Critical Care Impact".
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(179)
Lung Cancer Research Studies
(67)
Colorectal Cancer Treatments and Studies
(46)
Cancer Genomics and Diagnostics
(46)
Cancer Immunotherapy and Biomarkers
(39)
Affiliations
Ningbo University
Tongji University
University of Sydney
Union Hospital
Memorial Sloan Kettering Cancer Center